Last week on World Brain Tumour Day, QV Bioelectronics reached an important milestone in the development of GRACE, the world’s first fully implantable Tumour Treating Fields (TTF) device for glioblastoma.
The company submitted its final responses to the Research Ethics Committee as part of the approval process for SHIELD, QV’s first-in-human clinical study, which is planned to take place at Royal Melbourne Hospital in Australia.
Glioblastoma is the most common primary brain tumour in adults and remains one of the most challenging cancers to treat, with limited improvements in survival over recent decades. GRACE has been developed to address this unmet need through a fully implantable TTF system designed to deliver continuous treatment while minimising the burden associated with existing therapies.
SHIELD will be the first clinical study to evaluate a fully implantable TTF device in patients with glioblastoma and represents a significant step towards a new generation of treatment options designed around both efficacy and quality of life.
QV Bioelectronics would like to thank Professor Kate Drummond AM and the team at Royal Melbourne Hospital for their commitment and collaboration in bringing the study to this stage. The company also acknowledges the valuable support provided by Ascend Clinical throughout the submission process.
This milestone reflects the dedication of the entire QV Bioelectronics team and marks another important step towards bringing GRACE to patients. The company looks forward to the months ahead as it continues preparations for the study.
On World Brain Tumour Day, QV Bioelectronics also recognises the vital work of charities and advocacy organisations around the world, including The Brain Tumour Charity, Brain Tumour Research, and brainstrust, whose efforts continue to drive progress for patients and families affected by brain tumours.